Osthole

Osthole is a natural coumarin compound extracted primarily from Cnidium monnieri fruit that exerts its effects by modulating osteoblast and osteoclast activity, inflammatory cytokine signaling, and calcium channel function. Research in animal models suggests it may support bone density and reduce allergic airway inflammation, though human clinical trials remain limited.

Origin & History

Osthole is a naturally occurring coumarin compound (7-methoxy-8-(3-methylbut-2-enyl)coumarin) primarily extracted from the fruits and roots of medicinal plants like Cnidium monnieri and Angelica pubescens. Extraction typically involves solvent methods from these umbelliferous plants traditionally used in Chinese medicine.

Historical & Cultural Context

Osthole has been used in Traditional Chinese Medicine for centuries through herbs like Cnidium monnieri and Angelica pubescens, primarily for anti-inflammatory, analgesic, and reproductive health applications. Historical uses span treatments for vitiligo, osteoporosis, and seizures, with modern reviews confirming traditional applications in neuroprotection and immunomodulation.

Health Benefits

• May support bone health by increasing bone mineral density and inhibiting osteoclast proliferation (demonstrated in rat osteoporosis models, human studies needed)
• Shows potential anti-inflammatory effects by reducing Th2 cytokines (IL-4, IL-5, IL-13) and IgE levels (shown in mouse asthma models at 25-50 mg/kg)
• Demonstrates anti-cancer properties against intrahepatic cholangiocarcinoma cells (IC50 153-159 μM in cell studies, no human trials)
• May protect joint health by modulating collagen and MMP13 expression (shown in rat chondrocyte studies at 6.25-25 μM)
• Exhibits immunomodulatory effects by enhancing IL-10-producing dendritic cells and regulatory T cells (animal evidence only)

How It Works

Osthole promotes bone formation by activating the Wnt/β-catenin signaling pathway in osteoblasts while simultaneously suppressing RANKL-induced osteoclast differentiation, shifting the bone remodeling balance toward mineral deposition. In allergic inflammation, it downregulates GATA-3 transcription factor activity in Th2 lymphocytes, reducing secretion of interleukins IL-4, IL-5, and IL-13 and lowering IgE production. Osthole also acts as a calcium channel blocker and may inhibit phosphodiesterase (PDE), contributing to its smooth muscle relaxant and anti-spasmodic properties.

Scientific Research

Current evidence for osthole is limited to preclinical studies with no human clinical trials, RCTs, or meta-analyses identified. A meta-analysis of rat osteoporosis studies showed improved bone parameters, while mouse models demonstrated anti-inflammatory effects at 25-50 mg/kg oral doses. Cell line studies using 25-200 μM concentrations revealed anti-cancer mechanisms via PI3K/Akt pathway modulation.

Clinical Summary

The majority of osthole research comes from in vitro cell studies and rodent models, including ovariectomized rat osteoporosis models in which oral osthole administration increased bone mineral density by approximately 14–20% compared to controls. Mouse models of ovalbumin-induced asthma showed significant reductions in bronchoalveolar IL-4, IL-5, and IgE levels following osthole treatment. A small number of preliminary human pharmacokinetic studies have characterized its absorption and metabolite profile, but randomized controlled trials in humans evaluating efficacy for any indication are currently lacking. The overall evidence base is preclinical, and extrapolation to human therapeutic outcomes requires further investigation.

Nutritional Profile

Osthole (7-methoxy-8-(3-methyl-2-butenyl)-2H-chromen-2-one) is a pure isolated bioactive coumarin compound, not a whole food ingredient, and therefore contains no macronutrients (protein, fat, carbohydrates), dietary fiber, vitamins, or minerals. As a single phytochemical with molecular weight of 244.29 g/mol and molecular formula C15H16O3, its profile is defined entirely by its bioactive compound characteristics. It is naturally occurring in plants of the Apiaceae/Umbelliferae family, notably Cnidium monnieri seeds (containing approximately 0.1–1.2% osthole by dry weight), as well as Angelica pubescens and Peucedanum ostruthium. In experimental studies, active doses range from 25–50 mg/kg body weight (animal models). Bioavailability data indicates moderate oral absorption; osthole is lipophilic (logP approximately 3.5), facilitating membrane permeability, but undergoes significant first-pass hepatic metabolism via CYP450 enzymes (primarily CYP3A4 and CYP1A2), producing hydroxylated metabolites. Peak plasma concentration in rodent studies is reached within 1–2 hours post-oral administration. Its lipophilicity suggests improved absorption when co-administered with dietary fats. No clinically established human pharmacokinetic parameters are currently available. The compound exhibits estrogenic receptor partial agonism and calcium channel modulation activity at the molecular level.

Preparation & Dosage

No clinically studied human dosages are available. Preclinical studies used: oral doses of 25-50 mg/kg in mice for anti-inflammatory effects; 25-200 μM in cell culture studies (IC50 ~153 μM for anti-cancer effects); 6.25-25 μM for chondrocyte protection. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Calcium, Quercetin, Resveratrol, Curcumin

Safety & Interactions

Osthole has demonstrated a relatively favorable safety profile in animal toxicity studies at moderate doses, but high doses have shown hepatotoxic potential in rodent models, warranting caution with long-term or high-dose supplementation in humans. Because osthole inhibits CYP450 enzymes, particularly CYP3A4 and CYP2C9, it may increase plasma concentrations of co-administered drugs metabolized by these pathways, including warfarin, statins, and certain immunosuppressants. Its estrogenic activity in animal studies raises concern for use in individuals with hormone-sensitive conditions such as estrogen receptor-positive breast cancer, endometriosis, or uterine fibroids. Osthole is not recommended during pregnancy or breastfeeding due to insufficient safety data and its demonstrated uterine-stimulating effects in animal studies.